Comparison of hEBV321 and Bevacizumab binding properties to human VEGF.
- Yanlan Yu (367390)
- Pierre Lee (367391)
- Yaohuang Ke (367392)
- Yongke Zhang (367393)
- Qiu Yu (367395)
- Jonathan Lee (367397)
- Mingzhen Li (367398)
- Jialiang Song (367399)
- Jungang Chen (367400)
- Jihong Dai (367401)
- Fernando Jose Rebelo Do Couto (367402)
- Zhiqiang An (367403)
- Weimin Zhu (5970)
- Guo-Liang Yu (367404)
Publication date
February 2013
DOIAbstract
<p>A. VEGF competition ELISA measuring the binding of hEBV321 to VEGF coated on ELISA plate in the presence of increasing concentration of competitor (hEBV321, Bevacizumab or an irrelevant antibody Humira). B-E. Direct binding of hEBV321 and Bevacizumab to various forms of human VEGF captured on ELISA plate. B. VEGF wild type; C. VEGF I46A; D. VEGF G89A; E. VEGF G88A/Q89A.</p
Add to ORKG